These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 16274330)

  • 1. Cladribine for multiple sclerosis: review and current status.
    Sipe JC
    Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine. Ortho Biotech Inc.
    Tortorella C; Rovaris M; Filippi M
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1751-6. PubMed ID: 11892941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine: not just another purine analogue?
    Spurgeon S; Yu M; Phillips JD; Epner EM
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1169-81. PubMed ID: 19604118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
    Brousil JA; Roberts RJ; Schlein AL
    Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine as a therapeutic option in multiple sclerosis.
    Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP
    Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP; Weissert R
    Clin Neuropharmacol; 2011; 34(1):28-35. PubMed ID: 21242742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
    Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical pharmacology of 2-chlorodeoxyadenosine (Cladribine)].
    Góra-Tybor J; Robak T
    Przegl Lek; 1996; 53(8):614-8. PubMed ID: 8999463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B
    Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
    Janiec K; Wajgt A; Kondera-Anasz Z
    Med Sci Monit; 2001; 7(1):93-8. PubMed ID: 11208501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
    Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cladribine].
    Ogura M
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):309-17. PubMed ID: 12610885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine: from the bench to the bedside--focus on hairy cell leukemia.
    Greyz N; Saven A
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):745-57. PubMed ID: 15485311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
    Fabianowska-Majewska K; Wyczechowska D
    Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cladribine: limited evaluation in multiple sclerosis.
    Prescrire Int; 2011; 20(118):175. PubMed ID: 21751748
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging oral agents for multiple sclerosis.
    Fox EJ
    Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.